MarketCap
Facebook
X
TelegramAnnual report 2024
added 05-07-2025
Axon Enterprise DIO Ratio 2011-2025 | AXON
Annual DIO Ratio Axon Enterprise
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 116 | 518 | 123 | 112 | 88.8 | 63.4 | 76.3 | 121 | 130 | 83.1 | 106 | 78 | 85.3 | 92.1 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 518 | 63.4 | 128 |
Quarterly DIO Ratio Axon Enterprise
| 2025-Q1 | 2024-Q4 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 105 | - | - | 147 | 151 | 139 | - | 59.4 | 113 | 105 | - | 96.6 | 102 | 114 | - | 120 | 155 | 100 | - | 70 | 75.7 | 70.6 | - | 78.6 | 85.4 | 98.3 | - | 102 | 122 | 120 | - | 126 | 148 | 124 | - | 74.5 | 90 | 104 | - | 107 | 120 | 96.1 | - | 77.4 | 81.5 | 84.2 | - | 83.8 | 85.6 | 98.6 | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 155 | 59.4 | 104 |
DIO Ratio of other stocks in the Biotechnology industry
| Issuer | DIO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AbbVie
ABBV
|
89.4 | $ 223.01 | -0.99 % | $ 395 B |  USA |
 |
Aclaris Therapeutics
ACRS
|
42.1 | $ 3.38 | 3.21 % | $ 261 M | USA |
 |
Acasti Pharma
ACST
|
136 | - | 4.01 % | $ 150 M |  Canada |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
512 | - | - | $ 40.3 B | USA |
 |
Albireo Pharma
ALBO
|
26.1 | - | -0.23 % | $ 916 M | USA |
 |
Aptorum Group Limited
APM
|
4.89 | $ 1.33 | -1.48 % | $ 7.25 M |  China |
 |
AstraZeneca PLC
AZN
|
206 | $ 90.34 | -1.28 % | $ 96.9 B |  Britain |
 |
Amphastar Pharmaceuticals
AMPH
|
132 | $ 25.76 | 0.19 % | $ 1.25 B | USA |
 |
Anika Therapeutics
ANIK
|
247 | $ 9.53 | -1.19 % | $ 140 M | USA |
 |
BeiGene, Ltd.
BGNE
|
304 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Biogen
BIIB
|
394 | $ 173.03 | -2.55 % | $ 25.2 B | USA |
 |
Berkeley Lights
BLI
|
246 | - | -7.31 % | $ 87 M | USA |
 |
Aytu BioScience
AYTU
|
209 | $ 2.33 | 2.3 % | $ 14.6 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
160 | - | -6.81 % | $ 3.04 B | USA |
 |
Baudax Bio
BXRX
|
596 | - | 0.59 % | $ 63 K | USA |
 |
Catalyst Biosciences
CBIO
|
410 | $ 15.32 | 5.73 % | $ 1.01 B | USA |
 |
Институт стволовых клеток человека
ISKJ
|
275 | - | - | - |  Russia |
 |
ChromaDex Corporation
CDXC
|
114 | - | -0.88 % | $ 598 M | USA |
 |
Cerus Corporation
CERS
|
213 | $ 2.14 | 13.23 % | $ 395 M | USA |
 |
Caladrius Biosciences
CLBS
|
35.8 | - | -16.75 % | $ 25.8 M | USA |
 |
Clovis Oncology
CLVS
|
271 | - | -7.23 % | $ 13 M | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
2.04 K | - | - | $ 2.18 B | USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
239 | $ 11.55 | 8.86 % | $ 747 M | USA |
 |
Dynavax Technologies Corporation
DVAX
|
455 | $ 10.89 | -0.09 % | $ 1.42 B | USA |